Obesity and metabolic disease at TIDES Europe 2026
Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website
9 organizations at TIDES Europe 2026 present work in obesity & metabolic: 7 drug developers and 2 academic, government and non-profit bodies. Between them they bring 19 presentations to the program. Most represented: Novo Nordisk (6 on the program), Constructive Bio (2 on the program), Zealand Pharma (2 on the program). 5 of them have their own page in this guide. As of Sep 25, 2026.
Format
Top represented
Showing 1–9 of 9 organizations
| Organization | TIDES Europe 2026 Attendance |
|---|---|
Novo Nordisk Bagsværd, Denmark | |
Danish pharmaceutical company known for diabetes and obesity medicines, including the GLP-1 peptide drugs semaglutide and liraglutide. | Keynote Tue Nov 3 13:50–14:25 Next Generation GLP-1 Therapeutics How GLP-1 drugs for metabolic disease became longer-acting, and what it would take to dose them less often or swallow them as pills. PeptidesObesity & Metabolic Talk Wed Nov 4 08:05–08:35 Shifting Landscape: Global Regulatory CMC Guidance for Synthetic Oligonucleotides Where regulators around the world now agree and disagree on manufacturing and quality rules for synthetic oligonucleotides, and how those rules could align. Talk Thu Nov 5 09:05–09:35 Identity Testing of Synthetic Peptides: From Multi-Method Evaluation to a Compliant Two-Test Scheme Why two well-chosen laboratory tests can prove a manufactured peptide is the intended molecule, rather than the longer list of tests regulators expect. Talk Thu Nov 5 08:35–09:05 siRNA Conjugate Mediated Delivery to Disease Specific Cell Types Occurs through a Novel Mechanism How siRNA drugs attached to a carrier reach the cells behind chronic inflammatory disease and cancer, and how that route was worked out. Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. Talk Fri Nov 6 08:40–09:10 Keynote Presentation: Decoding The Future of Obesity Care: The Signals Worth Paying Attention To Where obesity drug development stands in 2026 and which companies and market openings across Europe are worth watching. Talk Fri Nov 6 12:00–12:25 |
CB Constructive Bio Cambridge, United Kingdom | |
Develops genetic code expansion technology to make proteins and peptides containing non-standard amino acids. | Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. Talk Fri Nov 6 13:30–13:45 |
Zealand Pharma Søborg, Denmark | |
Danish biotech developing peptide medicines for obesity and metabolic diseases, including amylin and GLP-1 analogues. | Talk Wed Nov 4 16:15–16:45 Dapiglutide: From Lab to Large Scale Manufacture through Innovative Peptide Process Development How process changes in making the peptide drug dapiglutide raised its overall yield from about 20% to over 60%. Talk Fri Nov 6 10:30–10:55 |
Develops oral treatments for obesity and metabolic disease, including a beaded glucose formulation that activates enteroendocrine cells. | Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. |
Silence Therapeutics London, United Kingdom | |
Develops siRNA medicines using its mRNAi GOLD platform for cardiovascular, haematological and other diseases. | Talk Wed Nov 4 10:15–10:45 Elongating siRNA Duration of Action by Enhanced Nuclease Resistance: End Stabilization Revisited A modification near each end of a siRNA made gene silencing in mice last longer while needing fewer sulfur linkages. |
Cantoni Therapeutics Oss, Netherlands | |
Leiden University spinout developing small molecule NNMT inhibitors for obesity and its cardiometabolic complications. | Talk Fri Nov 6 09:10–10:00 Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for. |
Erasmus MC Rotterdam, Netherlands | |
University medical center combining patient care, education and biomedical research. | |
GB Gordian Biotechnology | |
Drug discovery company using in vivo pooled screening, with programs in obesity and metabolic disease. | Talk Fri Nov 6 14:45–15:00 |
RU RCSI University of Medicine and Health Sciences Dublin, Ireland | |
Talk Fri Nov 6 13:45–14:00 |
Instantly find 20 buyers in obesity & metabolic
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse TIDES Europe 2026 by
Organization type
Focus
- Oligonucleotides 69
- Peptides 34
- CMC & Manufacturing 56
- Discovery & Clinical 29
- Obesity & Metabolic 9
Exhibit hall
Everyone
Not affiliated with or endorsed by Informa Connect or TIDES Europe. Submit a correction